1. Scrip
  2. >>Business

OSE Immunotherapeutics Seeks Partner For Lead Drug

 
• By Lucie Ellis-Taitt

Emerging Company Profile: Alexis Peyroles, chief operating officer of OSE Immunotherapeutics outlines the 2016-founded company's plans for commercializing its lead drug, Tedopi (OSE-2102).

Emerging Company Profile Regular column feature image Version 2
OSE Immunotherapeutics targets lead drug at NSCLC patients that don't benefit from PD-1s

OSE Immunotherapeutics SA was created in May 2016 through the merger of OSE Pharma, a company developing specific immunotherapy activating T lymphocytes, and Effimune SAS, a company specializing in immune regulation with clinical applications in autoimmunity, transplantation and immuno-oncology.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

More from Business

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.